Acrux

New Product Launches Including Cone 75% Will Expand Market Presence

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

13 May 25

AnalystConsensusTarget's Fair Value

AU$0.09

84.4% undervalued

04 Sep

AU$0.014

-75.9%

You can edit this narrative until May 13 8:13 PM. Then, changes will post as Updates.

Author's Valuation

AU$0.0984.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

AU$0.09

84.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

71.56%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$10.83m

Earnings '28

4.32x

PE Ratio '28

AU$46.83m

Market Cap '28

AU$46.83m

Market Cap '28

431.05m

No. shares '28

AU$0.11

Share Price '28

AU$0.11 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$0.09

Fair Value '25